NASDAQ:AZRX - AzurRx BioPharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.49 +0.02 (+0.81 %)
(As of 05/24/2018 08:00 AM ET)
Previous Close$2.47
Today's Range$2.42 - $2.52
52-Week Range$2.31 - $5.25
Volume37,000 shs
Average Volume43,097 shs
Market Capitalization$41.40 million
P/E RatioN/A
Dividend YieldN/A
Beta0.25

About AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma logoAzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855

Debt

Debt-to-Equity RatioN/A
Current Ratio0.64
Quick Ratio0.64

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book35.57

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,090,000.00
Net MarginsN/A
Return on Equity-468.72%
Return on Assets-181.43%

Miscellaneous

Employees13
Outstanding Shares16,760,000

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

How were AzurRx BioPharma's earnings last quarter?

AzurRx BioPharma (NASDAQ:AZRX) announced its earnings results on Monday, May, 14th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.11. View AzurRx BioPharma's Earnings History.

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for AzurRx BioPharma.

What price target have analysts set for AZRX?

1 brokers have issued 1-year price targets for AzurRx BioPharma's stock. Their predictions range from $8.00 to $8.00. On average, they anticipate AzurRx BioPharma's share price to reach $8.00 in the next year. View Analyst Ratings for AzurRx BioPharma.

Who are some of AzurRx BioPharma's key competitors?

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the folowing people:
  • Mr. Johan M. Spoor, Pres, CEO & Director (Age 46)
  • Mr. Maged S. Shenouda, CFO, Exec. VP & Director (Age 54)
  • Mr. Daniel Dupret, Chief Scientific Officer (Age 62)
  • Dr. Mathieu Schué Ph.D., Head of Laboratory
  • Mr. Martin Krusin, VP of Fin. & Bus. Devel.

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

Has AzurRx BioPharma been receiving favorable news coverage?

Media headlines about AZRX stock have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AzurRx BioPharma earned a media sentiment score of 0.19 on Accern's scale. They also gave press coverage about the company an impact score of 45.13 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are AzurRx BioPharma's major shareholders?

AzurRx BioPharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Parsons Capital Management Inc. RI (1.97%). View Institutional Ownership Trends for AzurRx BioPharma.

Which major investors are buying AzurRx BioPharma stock?

AZRX stock was purchased by a variety of institutional investors in the last quarter, including Parsons Capital Management Inc. RI. View Insider Buying and Selling for AzurRx BioPharma.

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $2.49.

How big of a company is AzurRx BioPharma?

AzurRx BioPharma has a market capitalization of $41.40 million. AzurRx BioPharma employs 13 workers across the globe.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]


MarketBeat Community Rating for AzurRx BioPharma (AZRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  114
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AzurRx BioPharma (NASDAQ:AZRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for AzurRx BioPharma in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 221.29%. The high price target for AZRX is $8.00 and the low price target for AZRX is $8.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$8.00$7.50
Price Target Upside: 221.29% upside164.03% upside134.60% upside158.62% upside

AzurRx BioPharma (NASDAQ:AZRX) Consensus Price Target History

Price Target History for AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma (NASDAQ:AZRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018HC WainwrightSet Price TargetBuy$8.00HighView Rating Details
12/6/2016WallachBeth CapitalInitiated CoverageBuy$7.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

AzurRx BioPharma (NASDAQ:AZRX) Earnings History and Estimates Chart

Earnings by Quarter for AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma (NASDAQ:AZRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.8 EPS
Next Year EPS Consensus Estimate: $-0.71 EPS

AzurRx BioPharma (NASDAQ AZRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
5/14/2018Q1 2018($0.18)($0.29)ViewN/AView Earnings Details
11/13/2017Q3 2017($0.15)($0.28)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.27)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.29)ViewN/AView Earnings Details
11/25/2016Q3 2016($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AzurRx BioPharma (NASDAQ:AZRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AzurRx BioPharma (NASDAQ AZRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 4.47%
Insider Trading History for AzurRx BioPharma (NASDAQ:AZRX)
Institutional Ownership by Quarter for AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma (NASDAQ AZRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2017Pelican Partners LlcMajor ShareholderSell160,000$3.19$510,400.001,787,796View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AzurRx BioPharma (NASDAQ AZRX) News Headlines

Source:
DateHeadline
 Brokerages Expect AzurRx BioPharma (AZRX) to Post -$0.18 Earnings Per Share Brokerages Expect AzurRx BioPharma (AZRX) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - May 14 at 9:12 PM
Zacks: Analysts Set $9.17 Target Price for AzurRx BioPharma (AZRX)Zacks: Analysts Set $9.17 Target Price for AzurRx BioPharma (AZRX)
www.americanbankingnews.com - May 12 at 11:13 PM
AzurRx BioPharma (AZRX) Rating Increased to Hold at ValuEngineAzurRx BioPharma (AZRX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM
AZRX: AzurRx Raises Capital After Confirming ResultsAZRX: AzurRx Raises Capital After Confirming Results
finance.yahoo.com - May 2 at 4:25 PM
AzurRx BioPharma (AZRX) Prices 4.16M Common Stock Offering at $2.50/ShareAzurRx BioPharma (AZRX) Prices 4.16M Common Stock Offering at $2.50/Share
www.streetinsider.com - May 1 at 4:18 PM
AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common StockAzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock
finance.yahoo.com - May 1 at 9:36 AM
AzurRx BioPharma Announces Proposed Public Offering of Common StockAzurRx BioPharma Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 30 at 4:20 PM
 Analysts Anticipate AzurRx BioPharma (AZRX) to Announce -$0.18 Earnings Per Share Analysts Anticipate AzurRx BioPharma (AZRX) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - April 27 at 8:33 AM
Zacks: AzurRx BioPharma (AZRX) Given $9.17 Consensus Price Target by AnalystsZacks: AzurRx BioPharma (AZRX) Given $9.17 Consensus Price Target by Analysts
www.americanbankingnews.com - April 27 at 5:18 AM
AzurRx BioPharma (AZRX) and Mayoly-Spindler Reports Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic InsufficiencyAzurRx BioPharma (AZRX) and Mayoly-Spindler Reports Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency
www.streetinsider.com - April 25 at 4:31 PM
HC Wainwright Reaffirms Buy Rating for AzurRx BioPharma (AZRX)HC Wainwright Reaffirms Buy Rating for AzurRx BioPharma (AZRX)
www.americanbankingnews.com - April 24 at 8:54 AM
AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI)AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI)
finance.yahoo.com - April 23 at 9:17 AM
AZRX: French Sites to Help Achieve 1H:18 Enrollment GoalAZRX: French Sites to Help Achieve 1H:18 Enrollment Goal
finance.yahoo.com - April 13 at 4:22 PM
Zacks: AzurRx BioPharma (AZRX) Given $9.17 Average Price Target by AnalystsZacks: AzurRx BioPharma (AZRX) Given $9.17 Average Price Target by Analysts
www.americanbankingnews.com - April 12 at 7:25 PM
FY2018 EPS Estimates for AzurRx BioPharma Decreased by Analyst (AZRX)FY2018 EPS Estimates for AzurRx BioPharma Decreased by Analyst (AZRX)
www.americanbankingnews.com - April 11 at 9:13 AM
 Brokerages Anticipate AzurRx BioPharma (AZRX) to Announce -$0.18 EPS Brokerages Anticipate AzurRx BioPharma (AZRX) to Announce -$0.18 EPS
www.americanbankingnews.com - April 10 at 9:10 AM
AzurRx BioPharma (AZRX) Given a $8.00 Price Target by HC Wainwright AnalystsAzurRx BioPharma (AZRX) Given a $8.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 6 at 11:07 AM
 AzurRx BioPharma Inc (AZRX) Given Consensus Recommendation of "Strong Buy" by Brokerages AzurRx BioPharma Inc (AZRX) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 26 at 11:10 PM
Analysts Anticipate AzurRx BioPharma Inc (AZRX) to Post ($0.24) Earnings Per ShareAnalysts Anticipate AzurRx BioPharma Inc (AZRX) to Post ($0.24) Earnings Per Share
www.americanbankingnews.com - March 8 at 9:06 PM
-$0.24 EPS Expected for AzurRx BioPharma Inc (AZRX) This Quarter-$0.24 EPS Expected for AzurRx BioPharma Inc (AZRX) This Quarter
www.americanbankingnews.com - March 7 at 5:44 AM
Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLCStock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC
finance.yahoo.com - March 2 at 9:28 AM
AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)
finance.yahoo.com - February 28 at 9:32 AM
Analyzing Collegium Pharmaceutical (COLL) and AzurRx BioPharma (AZRX)Analyzing Collegium Pharmaceutical (COLL) and AzurRx BioPharma (AZRX)
www.americanbankingnews.com - February 27 at 5:14 AM
Head to Head Review: Pacira Pharmaceuticals (PCRX) and AzurRx BioPharma (AZRX)Head to Head Review: Pacira Pharmaceuticals (PCRX) and AzurRx BioPharma (AZRX)
www.americanbankingnews.com - February 24 at 1:36 PM
 Brokerages Set $8.83 Price Target for AzurRx BioPharma Inc (AZRX) Brokerages Set $8.83 Price Target for AzurRx BioPharma Inc (AZRX)
www.americanbankingnews.com - February 21 at 12:05 PM
Novartis (NVS) versus AzurRx BioPharma (AZRX) Head-To-Head SurveyNovartis (NVS) versus AzurRx BioPharma (AZRX) Head-To-Head Survey
www.americanbankingnews.com - February 17 at 7:32 PM
AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SDAzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD
finance.yahoo.com - February 12 at 9:00 AM
AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)
finance.yahoo.com - February 9 at 9:07 AM
Head to Head Contrast: AzurRx BioPharma (AZRX) and Its RivalsHead to Head Contrast: AzurRx BioPharma (AZRX) and Its Rivals
www.americanbankingnews.com - February 6 at 5:10 PM
Zacks: AzurRx BioPharma Inc (AZRX) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: AzurRx BioPharma Inc (AZRX) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 6 at 9:14 AM
AzurRx BioPharma Inc (AZRX) Expected to Post FY2017 Earnings of ($1.03) Per ShareAzurRx BioPharma Inc (AZRX) Expected to Post FY2017 Earnings of ($1.03) Per Share
www.americanbankingnews.com - February 2 at 7:42 AM
AzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.24 Per ShareAzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - February 1 at 1:28 PM
 AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from Brokerages AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 31 at 1:18 AM
SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00
finance.yahoo.com - January 30 at 9:26 AM
Comparing AzurRx BioPharma (AZRX) and The CompetitionComparing AzurRx BioPharma (AZRX) and The Competition
www.americanbankingnews.com - January 28 at 9:26 AM
Financial Analysis: AzurRx BioPharma (AZRX) versus The CompetitionFinancial Analysis: AzurRx BioPharma (AZRX) versus The Competition
www.americanbankingnews.com - January 27 at 11:18 PM
Contrasting AzurRx BioPharma (AZRX) & The CompetitionContrasting AzurRx BioPharma (AZRX) & The Competition
www.americanbankingnews.com - January 27 at 9:14 PM
AzurRx BioPharma (AZRX) and XenoPort (XNPT) Head to Head AnalysisAzurRx BioPharma (AZRX) and XenoPort (XNPT) Head to Head Analysis
www.americanbankingnews.com - January 27 at 5:20 PM
Zacks: AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from AnalystsZacks: AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 25 at 3:14 PM
 AzurRx BioPharma Inc (AZRX) Given $8.25 Average Price Target by Brokerages AzurRx BioPharma Inc (AZRX) Given $8.25 Average Price Target by Brokerages
www.americanbankingnews.com - January 20 at 9:16 PM
AzurRx BioPharma (AZRX) PT Set at $8.00 by HC WainwrightAzurRx BioPharma (AZRX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - January 20 at 6:56 PM
AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic InsufficiencyAzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency
finance.yahoo.com - January 18 at 11:50 AM
AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of WarrantsAzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants
finance.yahoo.com - January 17 at 10:38 AM
AzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.23 Per ShareAzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 15 at 1:14 PM
Head to Head Comparison: AzurRx BioPharma (AZRX) and Its CompetitorsHead to Head Comparison: AzurRx BioPharma (AZRX) and Its Competitors
www.americanbankingnews.com - January 12 at 7:02 PM
AzurRx BioPharma (AZRX) & Its Peers Head to Head ComparisonAzurRx BioPharma (AZRX) & Its Peers Head to Head Comparison
www.americanbankingnews.com - January 10 at 12:12 PM
Reviewing AzurRx BioPharma (AZRX) & Its CompetitorsReviewing AzurRx BioPharma (AZRX) & Its Competitors
www.americanbankingnews.com - January 9 at 11:16 PM
 Brokerages Set $8.25 Target Price for AzurRx BioPharma Inc (AZRX) Brokerages Set $8.25 Target Price for AzurRx BioPharma Inc (AZRX)
www.americanbankingnews.com - January 5 at 5:50 PM
Zacks: AzurRx BioPharma Inc (AZRX) Given $8.25 Consensus Target Price by AnalystsZacks: AzurRx BioPharma Inc (AZRX) Given $8.25 Consensus Target Price by Analysts
www.americanbankingnews.com - January 2 at 9:14 PM
AzurRx BioPharma (AZRX) Announces Publication of U.S. Patent Application for AZX1101AzurRx BioPharma (AZRX) Announces Publication of U.S. Patent Application for AZX1101
www.streetinsider.com - December 20 at 10:48 AM

SEC Filings

AzurRx BioPharma (NASDAQ:AZRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AzurRx BioPharma (NASDAQ:AZRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AzurRx BioPharma (NASDAQ AZRX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.